SOPHiA GENETICS (SOPH) Company Report

SOPHiA GENETICS SA entered into a Second Amendment to its existing credit agreement with Perceptive Credit Holdings IV, LP on January 23, 2026, securing $25 million in additional term loan commitments.
These additional commitments include $12.5 million in Tranche C Term Loans and $12.5 million in Tranche D Term Loans, with the latter becoming available when the company's trailing twelve-month revenue exceeds $85 million.
If drawn, the Tranche C and Tranche D Term Loans will bear interest at Term SOFR + 6.25% and mature in 2029.
In connection with this amendment, SOPHiA GENETICS SA issued Perceptive Credit Holdings IV, LP the right to purchase an additional 75,000 ordinary shares immediately, with rights to purchase another 100,000 ordinary shares upon drawing Tranche C and an additional 100,000 ordinary shares upon drawing Tranche D.

Jan 28, 2026, 9:09 PM

6-K

SOPHiA GENETICS SA Announces CEO Transition and Preliminary 2025 Financial Results

SOPH

CEO Change

Management Change

Guidance Update

SOPHiA GENETICS SA announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026.
Dr. Jurgi Camblong, co-founder and current CEO, will transition to Executive Chairman of the Board.
For Q4 2025, the company expects preliminary unaudited revenue of at least $21 million, representing a 20% year-over-year increase.
For full-year 2025, preliminary unaudited revenue is expected to be approximately $77 million, an 18% year-over-year increase.
The company performed over 105,000 analyses on SOPHiA DDM in Q4 2025 (16% year-over-year growth) and over 391,000 analyses for full-year 2025, setting a new company record.

Jan 12, 2026, 3:48 PM

6-K

SOPHiA GENETICS Announces Preliminary Q4 and Full Year 2025 Results, 2026 Guidance, and CEO Transition

SOPH

Earnings

Guidance Update

CEO Change

SOPHiA GENETICS reported preliminary unaudited financial results for Q4 2025, with revenue of at least $21 million, representing an approximate 20% increase year-over-year, and full year 2025 revenue of approximately $77 million, an approximate 18% increase year-over-year.
The company initiated its FY 2026 guidance, projecting full year revenue between $92 million and $94 million, which represents approximately 20% to 22% year-over-year growth, and an adjusted EBITDA loss between $29 million and $32 million.
Ross Muken has been promoted to Chief Executive Officer, effective July 1, 2026, succeeding co-Founder Jurgi Camblong, who will transition to Executive Chairman of the Board.

Jan 12, 2026, 12:30 PM

6-K

SOPHiA GENETICS Reports Preliminary 2025 Results, Initiates 2026 Guidance, and Announces CEO Transition

SOPH

Earnings

Guidance Update

CEO Change

SOPHiA GENETICS reported preliminary unaudited financial results for Q4 2025, with revenue of at least $21 million (approximately 20% year-over-year increase), and full year 2025 revenue of approximately $77 million (approximately 18% year-over-year increase).
The company provided full year 2026 guidance, expecting revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth, and an Adjusted EBITDA loss between $29 million and $32 million.
Ross Muken has been promoted to Chief Executive Officer, effective July 1, 2026, succeeding co-Founder Jurgi Camblong, who will transition to Executive Chairman.

Jan 12, 2026, 12:00 PM

Press Release

SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration

SOPH

New Projects/Investments

Product Launch

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to accelerate AI-driven precision oncology.
The partnership involves launching research and development programs and co-developing an advanced next-generation sequencing oncology test built on the SOPHiA DDM™ Platform's AI algorithms.
This collaboration aims to enable clinicians to rapidly interpret complex RNA-sequencing data for cancer diagnosis and treatment, and to characterize tumor evolution in real time.

Jan 7, 2026, 1:00 PM

Press Release

SOPHiA GENETICS and Complete Genomics Announce Collaboration

SOPH

Product Launch

New Projects/Investments

SOPHiA GENETICS has announced a collaboration with Complete Genomics to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform.
This partnership aims to broaden access to precision oncology testing globally by offering an integrated, sample-to-report workflow for laboratories.
The collaboration integrates SOPHiA GENETICS' AI-powered applications with Complete Genomics' newly launched DNBSEQ-T1+ sequencing platform, expanding their presence in the precision oncology research market.
The new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient solution for comprehensive genomic profiling.

Nov 11, 2025, 2:00 PM

Press Release

SOPHIA GENETICS Updates 2025 Guidance and Reports Strong Q3 2025 Results

SOPH

Earnings

Guidance Update

Product Launch

SOPHIA GENETICS reported 23% year-over-year revenue growth and an adjusted gross margin of 73.1% for Q3 2025, with a cash balance of $81.6 million.
The company raised its 2025 revenue guidance to a range of $75 million to $77 million, representing 15% to 18% year-over-year growth, an increase from the prior range of $72 million to $76 million.
Strategic growth is driven by the adoption of MSK-ACCESS® powered by SOPHIA DDM™, which has been adopted by 60 leading institutions as of September 2025, and a partnership with AstraZeneca for global deployment.
SOPHIA GENETICS expanded its customer base by adding 31 new customers in Q3 2025 and achieved 108% Net Dollar Retention.

Nov 4, 2025, 1:00 PM

Presentation

SOPHiA GENETICS Reports Q3 2025 Results with Revenue Acceleration and Raised Guidance

SOPH

Earnings

Guidance Update

Revenue Acceleration/Inflection

SOPHiA GENETICS reported 23% year-over-year revenue growth in Q3 2025, marking the third consecutive quarter of acceleration.
The company raised its full-year 2025 revenue guidance to a range of $75 million-$77 million, representing 15%-18% growth.
In Q3 2025, SOPHiA GENETICS signed 31 new customers, bringing the total for 2025 to 94, surpassing the 92 customers signed in all of last year.
The company recorded an adjusted EBITDA loss of $10.2 million in Q3 2025 and ended the quarter with $81.6 million in cash and cash equivalents as of September 30.
Growth was driven by 30% year-over-year US revenue growth and over 300% year-over-year growth in MSK Access liquid biopsy analyses.

Nov 4, 2025, 1:00 PM

Transcript

SOPHiA GENETICS Reports Q3 2025 Results and Raises 2025 Revenue Guidance

SOPH

Earnings

Guidance Update

Revenue Acceleration/Inflection

SOPHiA GENETICS reported Q3 2025 revenue of $19.5 million, an increase of 23% year-over-year, with an IFRS net loss of $20.0 million.
The company updated its full-year 2025 revenue guidance to a range of $75 to $77 million, up from the prior range of $72 to $76 million, representing 15% to 18% year-over-year growth.
The Adjusted EBITDA loss for Q3 2025 was $10.2 million; however, excluding the impact of elevated Swiss social charges, the adjusted EBITDA loss would have been $8.8 million, representing a 13% year-over-year improvement.
Business highlights include a record 99,000 analyses performed on SOPHiA DDM™ and signing 31 new customers in Q3 2025, with the average contract value of new signings increasing by 180% year-over-year. The company also reaffirmed its commitment to profitable growth, expecting to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027.

Nov 4, 2025, 11:45 AM

Press Release

SOPHiA GENETICS Reports Q3 2025 Results and Raises Revenue Guidance

SOPH

Earnings

Guidance Update

Revenue Acceleration/Inflection

SOPHiA GENETICS reported revenue of $19.5 million for the third quarter ended September 30, 2025, representing a 23% year-over-year increase.
The company's net IFRS loss for Q3 2025 was $20.0 million, and the Adjusted EBITDA loss was $10.2 million. Excluding the impact of elevated Swiss social charges, the adjusted EBITDA loss would have been $8.8 million, representing a 13% year-over-year improvement.
SOPHiA GENETICS increased its full-year 2025 revenue guidance to a range of $75 to $77 million (up from $72 to $76 million), representing 15% to 18% year-over-year growth. The Adjusted EBITDA loss for the full year is now expected to be between $39 and $41 million.
During Q3 2025, the company performed a record 99,000 analyses on its SOPHiA DDM™ platform, a 9% year-over-year volume growth, and landed 31 new customers with an average contract value up 180% year-over-year.
The company noted potential impacts from a 39% U.S. tariff on goods imported from Switzerland, which could increase cost of revenue and operating expenses, and is monitoring potential changes to the Foreign Private Issuer (FPI) definition by the SEC.